TABLE 2:
Diagnosis1 | Baseline2 | Treatment phase | Observational phase | |||
---|---|---|---|---|---|---|
Polyps | Subjects3 | Polyps | Subjects3 | Polyps | Subjects3 | |
Sessile serrated adenoma/polyp | 18 | 17 | 128 | 96 | 79 | 62 |
SSA/P with cytological dysplasia | 12 | 11 | 4 | 4 | 3 | 3 |
Traditional serrated adenoma | 1 | 1 | 8 | 8 | 8 | 6 |
Serrated polyp not subclassified | 4 | 4 | 16 | 14 | 22 | 18 |
Hyperplastic polyp | 839 | 521 | 955 | 494 | 498 | 271 |
Total | 874 | 544 | 1111 | 565 | 607 | 329 |
Diagnosis at baseline is determined by the local pathologist at each clinical center. Post randomization polyps were all reviewed by the study pathologist.
Includes all randomized subjects and lesions found within 1 year of randomization
Participants with more than one type of serrated polyp may be represented multiple times. Total is the number of subjects with any serrated polyp, counting each subject only once if they had multiple types of serrated polyps